Ginkgo Bioworks to Go Public with Over $1.6 Billion in Proceeds
Upon the closing of the Business Combination (the Closing), Ginkgo Bioworks expects to receive $1.633 billion of gross proceeds, including $775 million in committed funding from a PIPE plus approximately $858 million from the Soaring Eagle trust account.
- Upon the closing of the Business Combination (the Closing), Ginkgo Bioworks expects to receive $1.633 billion of gross proceeds, including $775 million in committed funding from a PIPE plus approximately $858 million from the Soaring Eagle trust account.
- Ginkgo Bioworks is building the worlds leading horizontal platform for cell programming.
- In addition to its cell programming work, Ginkgo last year launched Concentric by Ginkgo, the companys public health and biosecurity initiative, to provide a response to the COVID-19 pandemic.
- Soaring Eagle and Ginkgo caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made.